Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Insider Sells $165,829.94 in Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 11,366 shares of the company's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $14.59, for a total transaction of $165,829.94. Following the completion of the transaction, the insider owned 97,907 shares of the company's stock, valued at $1,428,463.13. This trade represents a 10.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

David Malcom Rodman also recently made the following trade(s):

• On Wednesday, May 14th, David Malcom Rodman sold 11,366 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $15.29, for a total transaction of $173,786.14.

Mineralys Therapeutics Price Performance

MLYS stock traded down $0.09 during trading on Friday, reaching $14.25. The company had a trading volume of 688,167 shares, compared to its average volume of 562,260. Mineralys Therapeutics, Inc. has a 52 week low of $8.24 and a 52 week high of $18.38. The business has a 50 day moving average of $14.88 and a 200 day moving average of $13.09. The company has a market cap of $928.95 million, a P/E ratio of -3.83 and a beta of -0.30.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.79) EPS for the quarter, topping analysts' consensus estimates of ($1.02) by $0.23. Research analysts expect that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current year.

Analyst Ratings Changes

MLYS has been the subject of several analyst reports. Guggenheim set a $48.00 price target on shares of Mineralys Therapeutics and gave the company a "buy" rating in a research report on Wednesday, May 14th. HC Wainwright reaffirmed a "buy" rating and set a $42.00 price objective on shares of Mineralys Therapeutics in a research note on Tuesday, June 17th. Jefferies Financial Group initiated coverage on shares of Mineralys Therapeutics in a research note on Tuesday, June 10th. They set a "hold" rating and a $15.00 price objective for the company. Finally, Wall Street Zen downgraded shares of Mineralys Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $32.25.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of MLYS. RA Capital Management L.P. boosted its holdings in Mineralys Therapeutics by 26.7% in the 1st quarter. RA Capital Management L.P. now owns 6,147,280 shares of the company's stock worth $97,619,000 after buying an additional 1,296,296 shares during the period. SR One Capital Management LP boosted its holdings in Mineralys Therapeutics by 55.1% in the 1st quarter. SR One Capital Management LP now owns 3,127,933 shares of the company's stock worth $49,672,000 after buying an additional 1,111,111 shares during the period. Millennium Management LLC boosted its holdings in Mineralys Therapeutics by 1,015.8% in the 4th quarter. Millennium Management LLC now owns 1,101,674 shares of the company's stock worth $13,562,000 after buying an additional 1,002,941 shares during the period. Jennison Associates LLC boosted its holdings in Mineralys Therapeutics by 82.9% in the 1st quarter. Jennison Associates LLC now owns 1,979,033 shares of the company's stock worth $31,427,000 after buying an additional 897,027 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in shares of Mineralys Therapeutics by 42.1% during the 1st quarter. Vanguard Group Inc. now owns 2,035,506 shares of the company's stock valued at $32,324,000 after purchasing an additional 603,464 shares during the last quarter. Hedge funds and other institutional investors own 84.46% of the company's stock.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.